Latest1 information on COVID-19
©2022 Stanford Medicine
Not Recruiting
Trial ID: NCT01203358
Efficacy and Safety of Exosurf Neonatal and Survanta for the Treatment of Respiratory Distress Syndrome
Inclusion Criteria:
- Newborn infants weighing 501 to 1500 gm with respiratory distress syndrome were
receiving assisted ventilation with 30% oxygen or more
Exclusion Criteria:
- Less than 6 hours of age
drug: Exosurf
drug: Survanta
Not Recruiting
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305